Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 179, Issue -, Pages 376-388Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.06.068
Keywords
Nitroimidazole; Antibacterial; Antitubercular; Drug-resistant; Hybrid molecules; Structure-activity relationship
Categories
Funding
- Science & Technology Innovation Talents of Henan University of Chinese Medicine [2014XCXRC01]
- Henan University of Chinese Medicine, provincial scientific research business [2014KYYWF-ZZCX3-05]
Ask authors/readers for more resources
Infections especially tuberculosis caused by various bacteria including mycobacteria result in millions of lives every year, but the control of bacterial infections is challenged by the limitation of effective pharmaceuticals against drug-resistant pathogens. Nitroimidazoles belong to a group of nitroheterocyclic compounds that have broad-spectrum activity against a series of organisms such as mycobacteria, anaerobic Gram-positive and Gram-negative bacteria, and some of them have already been used in clinics or under clinical trials for the treatment of infectious diseases. In this review, we made an overview of the recent advances in nitroimidazole-containing compounds with antibacterial and antitubercular activity in the recent 20 years. (C) 2019 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available